News About: Pharm. Affairs
Bayer’s careless attitude over Aspirin recall angers pharmacies
Over the recovery of Bayer Aspirin, the pharmacy circles have made complaints over the attitude of the manufacturer Bayer and the previous seller Dong-A Pharm(agreement expired) for pushing jobs on each other.
Accord...
Pharmaceutical associations of various levels sill demand for sponsorship using superior status
It was criticized that asking distribution companies of every pharmaceutical association for sponsorship(?) using superior status still exists.
According to the pharmaceutical and distribution industries, it was obse...
Hanmi-MSD’s export agreement of ‘Rosuzet,’ hyperlipidemia combination drug, to 23 countries
Hanmi-developed ‘Rosuzet’ will be exported to 23 foreign countries via MSD.
It was announced on the 4th Hanmi Pharm and MSD has recently signed a license agreement of exporting Rosuzet and decided to export three dif...
Raphas selected as ‘World Class Company’ with transdermal technique ‘Microneedle Patch’
Raphas(CEO Do-Hyun Jung) announced the company and its ‘Hyaluronic Acid Patch’ were selected as the World Class Company of the Next Generation and World Class Product of the Next-Generation at the ‘2016 World Class Pr...
Be alerted on selling shortage-prevented drugs less than 91% of the upper limit price
Pharmaceutical manufacturers and importers were alerted because they will get charged if selling shortage-prevented drugs for less than 91% of their upper limit price from the January 1 2017.
The Korea Pharmaceutical...
Hanmi Pharm signs modified agreement of long-acting antidiabetic with Sanofi
Hanmi Pharm(CEO Kwan-Soon Lee) announced on the 29th that it signed a partial modification of the license agreement made on November 2015 for ‘Quantum Project,’ a long-acting antidiabetic portfolio, with Sanofi.
Acco...
Pharmacy circles’ difficulties in acquiring ‘Tamiflu’ over flu outbreak
In regards to the recent outbreaks of influenza virus(flu), the pharmacy circles are busy supplying ‘Tamiflu.’ Although the number of patients visiting hospitals and clinics for flu, the number of treatments is still ...
Daewoong Pharmaceutical’s open collaboration with Shenyang University
Daewoong Pharmaceutical(CEO Jong-Wook Lee) signed a memorandum of understanding(MOU) to cooperate with Shenyang University College of Pharmacy for joint research and development in various fields, such as new drug dev...
Yuhan recovers license for its non-small cell lung cancer therapy from Luoxin
Yuhan Corporation cancelled the technology export agreement of a targeted therapy for non-small cell lung cancer, YH25448, with a Chinese pharmaceutical company Luoxin Biotechnology.
According to Yuhan Coporation, th...
‘Pomalyst’ applied for insurance benefit while 48 products removed
From January next year, ‘Pomalyst Cap,’ a multiple myeloma treatment, will be applied for the health insurance benefit under the risk sharing(return type) application, and ‘Sunpla,’ a Korean new drug, will be removed ...
